POSTER: STEPWISE APPROACH TO AAV FULL CAPSID ENRICHMENT
Location Stevenage,
Great Britain
Published on Monday, January 6, 2025
Efficient AAV full capsid enrichment is essential for the success of gene therapy programs. At Rentschler Biopharma, we developed a scalable, cGMP-compliant process to separate full capsids from empty particles, ensuring high-quality vector production to meet your therapeutic goals.
Download our poster to explore how our stepwise methodology can help you achieve excellent results in AAV manufacturing.
Why full capsid enrichment is key to gene therapy success
- Enhanced Efficacy: Full capsids improve transduction efficiency, enabling lower dosages and reducing immunogenic risks.
- Scalable Solutions: Transition seamlessly from gradient elution to robust isocratic techniques, designed for cGMP readiness.
- Proven Results: Achieve a 5-fold increase in full AAV capsids, validated through mass photometry and ddPCR/ELISA.
What you’ll learn from this poster
- Screening Strategies: Insights into selecting and optimizing AEX media for effective empty/full separation.
- DoE-Driven Optimization: Key findings from our Design of Experiment (DoE) approach to elution parameters.
- Process Refinement: Techniques for scalable solutions tailored to meet manufacturing demands.
Download the poster and elevate your AAV manufacturing process: